Skip to main content
. 2019 Aug;7(16):387. doi: 10.21037/atm.2019.07.43

Figure 2.

Figure 2

Changes in the quantities of CD8, PD-L1, CD20, and Foxp3-positive lymphocytes and PD-L1-positive tumor cells. (A) Mean or median positive lymphocytes for CD8 and Foxp3 and positivity for PD-L1 and CD20 in STS between the 1st and 2nd surgery; (B) change in the number of CD8-positive lymphocytes; (C) change in PD-L1 positivity in tumor cells (T); (D) change in PD-L1 positivity in lymphocytes (L); (E) change in CD20 positivity; (F) Change in the number of Foxp3-positive lymphocytes. PD-L1, programmed cell death ligand 1; PD-L1(T), PD-L1 in tumor cells; PD-L1(L), PD-L1 in lymphocytes; STS, soft tissue sarcomas.